C5 and paroxysmal nocturnal hemoglobinuria: Food and Drug Administration (FDA) approved Eculizumab (anti-C5 antibody) for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in 2007 (125), 40 years after the demonstration that complement was the principal cause of this devastating disease (126, 127).